– USA, MA – AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that John Fallon, M.D., senior vice president and chief physician executive at Blue Cross & Blue Shield of Massachusetts (BCBSMA), has been elected to AMAG’s board of directors, effective September 5, 2014.
Dr. Fallon brings to the AMAG board broad-based payer, managed care and physician group practice management experience, as well as expertise obtained through his distinguished 25-year career in a variety of physician hospital organizations, integrated delivery systems and academic medical centers. During his tenure at BCBSMA, Dr. Fallon has been responsible for ensuring the highest standards of medical care for the health plan’s nearly 3 million members. He is also responsible for helping to expand health care strategies around quality, effectiveness and efficiency.
“John’s deep experience in leadership roles on the delivery side of the healthcare continuum will be of great value to AMAG and complements our current board,” said Gino Santini, chairman of the board of AMAG. “We are pleased to have John join us as the company continues to implement its strategic plan, growing our current products and seeking additional products to expand and diversify the portfolio.”
Prior to his role at BCBSMA, Dr. Fallon served as chief executive officer for clinical affairs at the State University of New York Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty practice plan. His professional experience also includes the Partners Healthcare System, where he was chairman of the physician network. Dr. Fallon was also the founder and CEO of North Shore Health System, a large physician-hospital organization in Massachusetts. He serves on the board of directors of Insulet Corporation, as well as several not-for-profit boards, including NEHI (Network for Excellence in Health Innovation) (Chair), National Committee for Quality Assurance(NCQA) Medical Standards (Chair), New England Comparative Effectiveness Public Advisory Council(CEPAC) and Temple University School of Medicine Board of Advisors.
“I am very excited about joining the AMAG board at this time,” said Dr. Fallon. “AMAG has an impressive record of achievement over the past couple of years, and I look forward to working with the board and management to help the company build on those successes.”
Dr. Fallon practiced internal medicine for more than 20 years, fulfilled his residency at Boston City Hospital, is Board Certified in Internal Medicine and is a fellow of the American College of Physicians. He received a bachelor’s degree from the College of the Holy Cross, a master’s degree in business administration from the University of South Florida and a medical degree from Tufts University School of Medicine.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in the United States. Along with driving continued growth of its products, AMAG intends to continue to expand its portfolio through the in-license or purchase of additional pharmaceutical products or companies, including revenue-generating commercial products and late-stage development assets that leverage its corporate infrastructure and commercial expertise. Our primary goal is to bring to market therapies that provide clear benefits and improve patients’ lives.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.